Myriad Genetics (MYGN) Tops Q3 EPS by 5c

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $191.9 million versus the consensus estimate of $179.23 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c